LivaNova (LIVN) AI Stock Analysis

With EPS of 4.21 and a PE ratio of 18.58, LivaNova appears reasonably valued relative to typical medtech peers, suggesting neither clear overvaluation nor deep value. The earnings profile implies solid underlying profitability, but without multi-period revenue or margin data, it is difficult to confirm a strong growth or margin expansion story.

• EPS of 4.21 combined with a PE of 18.58 implies the market is pricing in moderate, not hyper-growth, expectations for a profitable medtech business.
• The valuation multiple is consistent with a company that is profitable but not currently viewed as a high-growth outlier, supporting a balanced risk‑reward profile.
• Lack of detailed revenue and margin trend data prevents a more decisive view on operating leverage and long-term earnings trajectory, keeping the stance neutral.

At $78.21, LivaNova trades meaningfully above its 200-day moving average of $68.28, indicating a generally positive intermediate-term trend despite a 2.0% pullback over the last month. The recent decline looks more like a short-term consolidation within an uptrend than a clear reversal, but without RSI data, overbought/oversold conditions cannot be confirmed.

• Price is roughly 14–15% above the 200-day moving average ($78.21 vs. $68.28), a classic sign of an established uptrend on longer time frames.
• The 2.0% decline over the past month suggests mild near-term weakness or consolidation rather than a sharp breakdown, which tempers but does not negate the positive trend.
• Absence of RSI data limits insight into momentum extremes, so the technical picture leans constructive but not strongly enough to be labeled clearly bullish.

Alternative data for LivaNova is mixed to mildly soft: web traffic is modest, job openings have declined slightly month over month, and social media followings are small with only marginal growth. These indicators suggest stable but not accelerating commercial or brand momentum.

• Estimated monthly web traffic of 71,825 visitors is moderate for a specialized medtech company and does not signal a surge in customer or stakeholder engagement.
• Job openings at 155, down 1.9% month over month, point to cautious or stable hiring rather than aggressive expansion, implying measured growth expectations.
• Social media audiences (6 on X, 3,730 on Facebook, 1,730 on YouTube) are small with only 0.6% growth over 90 days on key platforms, indicating limited digital brand momentum and weak signal for near-term demand acceleration.

Overall, LivaNova’s stock setup appears neutral: the company is profitable and trades at a reasonable multiple, and the price is in an intermediate-term uptrend despite a recent pullback. However, alternative data do not point to strong growth acceleration, keeping the risk‑reward balanced rather than clearly skewed bullish or bearish.

• Profitability and a fair valuation multiple, combined with a price above the 200-day moving average, support a constructive but measured view.
• Soft-to-flat alternative data (web traffic, hiring, and social media growth) and a recent 1‑month price decline argue against a strongly bullish stance, resulting in an overall neutral outlook.